VAXXITEK® HVT+IBD

A Lifetime of Immunity.

VAXXITEK® HVT+IBD is an innovative, safe and effective vector vaccine that provides early protection against classic, variant, and very virulent pathotypes of IBD virus and Marek’s disease.1

  • VAXXITEK HVT+IBD is an HVT-based vector vaccine
  • Contains the viral VP2 protein to stimulate IBD immunity
  • Systemic replication of the vector induces protection against 2 important diseases

Key Advantages

  • One single vaccination to protect against IBD and MD
  • Only one hatchery administration at day-old or in ovo
  • Early onset of immunity, no immunity gap2
  • Immune protection against classic, variant, and vvIBD from 14 days of age3
  • Onset of immunity against MD shown from 4 days of age3
  • Improved bursal health4
  • Up to 10 week duration of immunity5
  • Improved flock uniformity6
  • Controlling immunosuppression will reduce the need for antibiotics7
  • No interference with maternal antibodies5
  • Excellent primer and is effective in all types of poultry businesses – broiler, layer, and breeder chickens
  • HVT and VP2 will induce immune responses that protect against both IBD and MD4
  • VP2 elicits neutralizing antibodies
  • More than 70 scientific papers published to date8
  • 100 billion birds vaccinated since first launch in 20069
  • Package in 5 x 2,000 and 5 x 4,000 dose ampules in frozen presentation
  • Do not mix with other products, except as specified on the label
  • In case of human exposure, contact a physician
  • Administer only as recommended
  • Use entire contents when first opened
  • Do not vaccinate within 21 days before slaughter
  • Contains penicillin and streptomycin sulfate which are added as bacteriostatic agents
  • Contains Amphotericin B as a fungistatic agent
  • Inactivate unused contents before disposal

VAXXITEK HVT + IBD References:

  1. Rautenschlein S, Simon B, Jung A, Pöppel M, Prandini F, Lemiere S. Protective efficacy of VAXXITEK HVT + IBD in commercial layers and broilers against challenge with very virulent infectious bursal disease virus. 16th congress of the World Veterinary Poultry Association, Marrakesh, Morocco, 2009.
  2. Le Gros F-X, Dancer A, iacomini C, Pizzoni L, Bublot M, Graziani M, Prandini F. Field efficacy trial of a novel HVT-IBD vector vaccine for 1-day-old broilers, Vaccine. 2009;27:592-596.
  3. Cruz-Coy J, Oliveira C, Pereira J, Ambrosino F, Gaudenci A, Le- Gros FX, Pritchard N. Efficacy of a Turkey Herpesvirus HVT-MDV serotype-3)-Infectious Bursal Disease (IBD) Vaccine, Live HVT Vector, IBD-VP2, Administered in ovo and to One-Day-Old SPF Chickens. Poster presentation. American Association of Avian Pathologists convention, Hawaii, United States of America. 2006; p135.
  4. Bublot M. Vector vaccines for poultry: their advantages and limitations compared to classical vaccines. Proceedings of the International Symposium on Poultry Diseases, 14-15 Dec 2015.
  5. Bublot M, Prithcard N, Le Gros F-X, Goutebroze S. Use of a vectored vaccine against infectious bursal disease of chickens in the face of high-titred maternal derived antibody. Journal of Comparative Pathology, 2007;137:81-84.
  6. Garritty AT. The effect of vectored HVT+IBD (Vaxxitek® HVT + IBD) vaccination on body weights, uniformity and virus shedding in commercial broilers. Abstract. International Poultry Scientific Forum, Atlanta, 2011; p31.
  7. Lemiere S, Rojo R, He S, Tang S, Li W, Herrmann A, Prandini F. Benefits of the Herpesvirus of Turkey vector vaccine of Infectious Bursal Disease in control of immune-depression in broilers and decrease of use of antibiotic medication. Abstract. XVIIIth Congress of the World Veterinary Poultry Association, Nantes, France, 2013; in-press.
  8. Data on file at Boehringer Ingelheim.
  9. Data on file at Boehringer Ingelheim.

VAXXITEK® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc.
POU-0046-POUL0219

Product Resources

Contact Information

  • Boehringer Ingelheim Animal Health USA Inc.

    Poultry Business Unit

    3239 Satellite Blvd.
    Duluth, GA 30096